Stage 01
Myeloid
Signature BML+
AML, MDS and MPN, therapy-related and transformed disease, with staged reporting so the findings that change the first cycle arrive first.
See BML+Pillar 2 · the tests that feed a decision
Signature
Molecular tests for solid tumours and blood cancers. Each reads the DNA of the cancer and feeds the result into Blueprint Care, where it becomes a signed decision.
The molecular tests
The test that feeds the decision
Signature reads the DNA of the cancer, from a blood draw, a bone marrow sample or a tissue block, and feeds the result into Blueprint Care where it becomes a ranked, signed decision.
Signature is the test. Blueprint Care is the decision.
6tests across both families
523genes on the widest panel
35PGx genes in every solid-tumour tier
2assay families: solid and blood
Solid tumour and blood cancer
Every Signature test
Two assay families, because solid tumours and leukaemias are driven by different biology and need different panels, plus a custom route for the questions neither catalogue answers.
Blood cancer
Designed for one question
Lineage decides, not breadth
Choosing a blood cancer panel
There are two Signature B panels and both read more than 600 genes. The choice is lineage, not how much breadth the case can justify. BML+ reads myeloid disease and carries the lymphoid genes an ambiguous presentation needs; BLL+ reads lymphoid disease and carries the lymphoma overlap.
Stage 02
Lymphoid
Signature BLL+
Lymphoblastic leukaemia and the lymphoma overlap, with Philadelphia-like detection, copy number and clonality.
See BLL+| BML+ | BLL+ | |
|---|---|---|
| Lineage covered | Myeloid, with lymphoid overlap | Lymphoid, with lymphoma overlap |
| Genes read | 600+ | 600+ |
| Point mutations and InDels | Yes | Yes |
| Fusions and rearrangements | Yes | Yes |
| Copy number | Yes | Yes |
| Philadelphia-like signature | Not applicable | Yes |
| MDS and MPN overlap genes | Yes | No |
| Lymphoma overlap genes | Limited | Yes |
| Germline predisposition flags | Yes | Yes |
| Clonal architecture | Yes | Yes |
| Monitoring baseline | Yes | Yes |
| Staged urgent reporting | Yes | Where the presentation is acute |
Signature Custom
When none of these fits
Some questions are not on any catalogue. A rare sarcoma defined by one fusion, a glioma whose classification depends on IDH, 1p/19q and MGMT together, a GIST where the exact exon changes the answer, or a research programme with fixed requirements. For those, the panel is designed around the question instead.
By the question you need answered
Choosing a solid-tumour tier
Stage 01
Fastest
Signature STb
33 actionable genes and 13 fusion genes from blood. For urgent decisions.
See STbStage 02
Baseline
Signature STb O
118 genes from blood. Broad, and the baseline Sentinel monitoring needs.
See STb OStage 03
Fullest
Signature STb O+
523 genes plus copy number, fusions and signatures. The complete liquid-biopsy picture.
See STb O+Stage 04
Tissue
Signature STt O
Comprehensive profiling direct from an FFPE tumour block.
See STt O
No confusing add-ons
What every tier includes
The markers your doctor needs are built into every tier, not sold separately.
Driver mutations
SNVs and InDels across the tier’s gene set.
Gene fusions
Rearrangements for the relevant targets.
Immune profile
TMB, MSI and MMR reported on every tier.
Pharmacogenomics
The 35-gene drug-response panel.
Copy number and signatures
From the 118-gene tier upward.
Tumour fraction
How much tumour DNA was present, so results are read in context.
35 genes, every tier
The pharmacogenomics panel
Beyond what drives the cancer, we read how you are likely to handle the drugs used to treat it. This can prevent severe reactions and guide safe dosing before the first dose.
Drug metabolism and response
25 genesHow you process and react to common cancer drugs.
- DPYD
- UGT1A1
- TPMT
- NUDT15
- CYP2D6
- CYP2C19
- CYP3A5
- CYP2B6
- CYP2C9
- VKORC1
- ABCB1
- ABCG2
- SLCO1B1
- SLC22A1
- SLC22A2
- CYP3A4
- CYP1A2
- GSTP1
- GSTA1
- GSTM1
- GSTT1
- TYMS
- MTHFR
- ENOSF1
- CES2
Drug hypersensitivity (HLA)
4 genesFlags risk of severe, sometimes fatal, skin or hypersensitivity reactions.
- HLA-B*57:01
- HLA-B*58:01
- HLA-B*15:02
- HLA-A*31:01
Antibody response
2 genesInfluences how well certain therapeutic antibodies engage the immune system.
- FCGR2A
- FCGR3A
DNA repair and platinum response
4 genesRelates to how a tumour responds to platinum chemotherapy.
- ERCC1
- ERCC5
- XRCC1
- XRCC3
Pharmacogenomics is a safety net, and safety nets should never be optional.
DPYD
Predicts severe toxicity from fluoropyrimidines such as 5-FU and capecitabine.
UGT1A1
Guides safe dosing of irinotecan.
TPMT and NUDT15
Predict toxicity from thiopurines, important in leukaemia regimens.
Blood or tissue?
- Question 1Do you have a usable tumour block?
If a recent FFPE block exists and tissue is preferred, choose STt O.
- Question 2Is surgery difficult, or is timing urgent?
A blood draw avoids a surgical biopsy and can be faster.
- Question 3How much breadth do you need?
Fast and actionable: STb. Broad plus monitoring: STb O. The fullest picture: STb O+.
What a Signature test cannot do
A negative result means the tested genes carried no reportable changes. It does not mean cancer is absent, and it does not rule out alterations outside the panel.
Liquid biopsies depend on tumour DNA shedding. Occasionally, changes seen in blood come from normal ageing blood cells rather than the tumour. Every report states these limits plainly, and a clinician reads the result alongside your full clinical picture.
Research and evidence
The science behind this
Liquid-biopsy and tissue comprehensive profiling are validated in large studies and recommended by international guidelines.
Study 1
Blood-based profiling, extensively validated
A cfDNA comprehensive genomic profiling assay was validated across more than 7,500 tests and over 30,000 variants, spanning 300+ genes and 30+ cancer types.
Woodhouse R, et al. PLoS ONE, 2020.
Study 2
Guidelines support ctDNA profiling
NCCN and ESMO recommend ctDNA profiling as an alternative or complement to tissue. ASCO recommends blood cfDNA as the specimen of choice for comprehensive profiling in advanced breast cancer.
Review, Cancers, 2022.
Study 3
Plasma genotyping finds more targets
Adding plasma ctDNA testing to tissue in advanced lung cancer increased detection of targetable alterations and the number of patients who received matched therapy.
Aggarwal C, et al. JAMA Oncology, 2019.
These independent, peer-reviewed studies describe the class of technology we use. They are shared for education. They are not results for any individual and not a promise of benefit.
Being clear about our limits
What we do and do not do
What we DO
- Read the tumour’s drivers, fusions, immune and PGx profile
- Feed a ranked, tumour-board-signed Blueprint Care decision
- Report tumour fraction and per-gene coverage openly
- Work from blood or tissue, and repeat over time when needed
What we DON’T do
- Diagnose cancer or decide treatment on their own
- Rule out cancer from a “not detected” result
- Detect changes in genes outside the panel
- Guarantee a drug, its approval, cover, or that it will work
Plain-language glossary (9 terms)
| Term | What it means |
|---|---|
| ctDNA | Circulating tumour DNA, tumour fragments in blood that a liquid biopsy reads. |
| SNV / InDel | A single-letter DNA change, or a small insertion or deletion. |
| Fusion | Two genes joined abnormally, creating a driver that is often highly treatable. |
| CNV | Copy-number variation, extra or missing copies of a gene. |
| TMB | Tumour mutational burden, how many mutations a tumour carries. |
| MSI / MMR | Signals of faulty DNA repair that often predict immunotherapy response. |
| PGx | Pharmacogenomics, how your genes affect the way you handle specific drugs. |
| Tumour fraction | How much of the blood DNA came from the tumour. |
| CCR | Complete coding region, meaning the whole gene is read rather than known hotspots. |
Take the next step
Three ways forward. Pick the one that fits today.
Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationBegin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal